

Publications 2013

Equipe de Recherche / Research Team

Immunité et immunogénétique antivirale et vaccinale / Immunity and immunogenetics against viruses and vaccines

Chef d'équipe / Team Leader

Prof. Brigitte AUTRAN

1. Hoarau JJ, Gay F, Pellé O, **Samri A**, Jaffar-Bandjee MC, Gasque P, **Autran B**. Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005-2006 in La Reunion Island. PLoS One. 2013 Dec 23;8(12):e84695
2. Pogliaghi M, **Papagno L**, Lambert S, Calin R, Calvez V, Katlama C, **Autran B**. The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients. AIDS. 2014 Jan 14;28(2):278-81.
3. Dhédin N, Krivine A, Le Corre N, Mallet A, Lioure B, Bay JO, Rubio MT, Agape P, Thiébaud A, Le Goff J, **Autran B**, Ribaud P. Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. Vaccine. 2014 Jan 23;32(5):585-91. doi: 10.1016/j.vaccine.2013.11.073.
4. Fourati S, Flandre P, Calin R, **Carcelain G**, Soulie C, Lambert-Niclot S, Maiga A, Ait-Arkoub Z, Tubiana R, Valantin MA, **Autran B**, Katlama C, Calvez V, Marcelin AG. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. J Antimicrob Chemother. 2014 Mar;69(3):753-6.
5. Psomas C, Lavigne JP, Barbuat C, Trabelsi S, Ghosn J, Lascoux-Combe C, Flandre P, Cuzin L, Reynes J, **Autran B**, Corbeau Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals. P. Blood. 2013 Sep 26;122(13):2282-3.
6. Roux A, Mourin G, **Larsen M**, **Fastenackels S**, Urrutia A, **Gorochov G**, **Autran B**, Donner C, Sidi D, Sibony-Prat J, Marchant A, Stern M, **Sauce D**, **Appay V**. Differential impact of age and cytomegalovirus infection on the $\gamma\delta$ T cell compartment. J Immunol. 2013 Aug 1;191(3):1300-6.
7. **Carcelain G**, **Autran B**. Immune interventions in HIV infection. Immunol Rev. 2013 Jul;254(1):355-71.
8. Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, Lascoux-Combe C, Slama L, Allegre T, Allavena C, Yazdanpanah Y, Duvivier C, Katlama C, Goujard C, Seksik BC, Leplatois A, Molina JM, Meyer L, **Autran B**, Rouzioux C; OPTIPRIM ANRS 147 study group. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One. 2013 May 14;8(5):e64219.
9. Roux A, Mourin G, **Fastenackels S**, **Almeida JR**, Iglesias MC, Boyd A, Gostick E, **Larsen M**, Price DA, Sacre K, Douek DC, **Autran B**, Picard C, Miranda Sd, **Sauce D**, Stern M, **Appay V**. CMV driven CD8(+) T-cell activation is associated with acute rejection in lung transplantation. Clin Immunol. 2013 Jul;148(1):16-26.
10. Lécuroux C, Girault I, Chéret A, Versmisse P, Nembot G, Meyer L, Rouzioux C, Pancino G, Venet A, Sáez-Cirión A; ANRS 147 OPTIPRIM clinical trial. CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection. PLoS One. 2013;8(3):e59767.
11. Katlama C, Deeks SG, **Autran B**, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013 Jun 15;381(9883):2109-17.
12. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lécuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, **Autran B**, Rouzioux C; ANRS

- VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. *PLoS Pathog.* 2013 Mar;9(3):e1003211.
13. **Autran B**, Descours B, Bacchus C. Immune control of HIV-1 reservoirs. *Curr Opin HIV AIDS.* 2013 May;8(3):204-10.
 14. Antoni G, Guergnon J, Meaudre C, **Samri A**, Boufassa F, Goujard C, Lambotte O, **Autran B**, Rouzioux C, Costagliola D, Meyer L, **Theodorou I**. MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection. *AIDS.* 2013 Jul 17;27(11):1707-16.
 15. García F, Climent N, Guardo AC, Gil C, León A, **Autran B**, Lifson JD, Martínez-Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07-ORVACS Study Group. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. *Sci Transl Med.* 2013 Jan 2;5(166):166ra2.
 16. Descours B, Lambert-Niclot S, Mory B, **Samri A**, Charlotte F, Peytavin G, Tubiana R, **Papagno L**, Bacchus C, Lecardonnel F, Katlama C, **Autran B**, Marcelin AG, Valantin MA, Carcelain G; DECAMUNE and ORVACS Study Groups. Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIV-infected patients. *J Acquir Immune Defic Syndr.* 2013 Mar 1;62(3):255-9.